Some Stocks That May Be Hidden Gems
While most investors try to follow bubbles or pick over popular stocks for a little bit of profit, these undervalued companies may be poised for a bit of growth.
stem cells
Inside Wall Street: This Tiny Stem Cell Biotech Has the Vatican's Backing
Stem cell research is still too hot for most investors, but NeoStem is starting to change that, thanks to some unexpected events. Among them are the Catholic Church's surprising embrace of NeoStem's research and NeoStem's foothold in China's vast health care market.
Court Ruling Pressures Stem Cell Stocks
Companies involved in researching medical techniques using stem cells saw shares tumble across the board Tuesday, a day after a federal court ruled to block government funding for stem cell research.
Potential Paralysis Cure Pushes Shares of StemCells Up
StemCells Inc. shares jumped some 14% after the company reported new preclinical data showing its proprietary human neural stem cells restore lost motor function in mice long after their spinal cord injuries.
Stem Cell Therapies: Is Now the Time to Invest?
For investors on the hunt for groundbreaking technologies, stem cell therapies looked promising. But while the world waited for new treatments, Wall Street lost interest. Now, the science is accelerating, but stock prices haven't caught up.
Pfizer Invests in Stem Cell Therapy
Long an old-line drug company, Pfizer is looking increasingly like a new biotech these days, especially after licensing a stem cell therapy. Athersys' MultiStem is a therapy that consists of a special class of stem cells obtained from the bone marrow of healthy, adult donors to treat inflammatory bowel disease.
